Poseida Therapeutics, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In the top alliance by deal value, Arrowhead Pharmaceuticals granted Sarepta Therapeutics exclusive global rights to four clinical and three preclinical programs in rare, genetic diseases of the muscl

Roche has sought to temper the long-expected news that its cancer immunotherapy, tiragolumab, has failed in a key Phase III study by announcing a $1.5bn buyout of the cell therapy company Poseida .